Bupivacaine Hydrochloride Patent Expiration
Bupivacaine Hydrochloride is Used for providing post-surgical analgesia through local anesthesia for up to 24 hours following implantation. It was first introduced by Hospira Inc
Bupivacaine Hydrochloride Patents
Given below is the list of patents protecting Bupivacaine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xaracoll | US11746141 | Modified collagen | Jan 09, 2033 | Innocoll Pharms |
| Xaracoll | USRE47826 | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage | May 20, 2029 | Innocoll Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Bupivacaine Hydrochloride's patents.
Latest Legal Activities on Bupivacaine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Bupivacaine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical
| 05 Sep, 2023 | US11746141 |
| Recordation of Patent eGrant | 05 Sep, 2023 | US11746141 |
| Recordation of Patent Grant Mailed Critical
| 05 Sep, 2023 | US11746141 |
| Patent eGrant Notification | 05 Sep, 2023 | US11746141 |
| Mail Patent eGrant Notification | 05 Sep, 2023 | US11746141 |
| Email Notification Critical
| 05 Sep, 2023 | US11746141 |
| Email Notification Critical
| 18 Aug, 2023 | US11746141 |
| Issue Notification Mailed Critical
| 16 Aug, 2023 | US11746141 |
| Dispatch to FDC | 20 Jul, 2023 | US11746141 |
| Application Is Considered Ready for Issue Critical
| 20 Jul, 2023 | US11746141 |
Bupivacaine Hydrochloride's Family Patents
